Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Bavarian Nordic is a Danish biotechnology company specializing in vaccines for infectious diseases and cancer immunotherapies. The company is best known as the sole FDA-approved manufacturer of smallpox/mpox vaccines (JYNNEOS/Imvanex), which drove exceptional revenue in 2022-2023 during the global mpox outbreak. With the outbreak subsiding, the company faces normalization of vaccine demand while advancing its pipeline of travel vaccines and oncology candidates.
Bavarian Nordic generates revenue through direct vaccine sales to governments (primarily US and European stockpiling contracts), commercial sales of travel vaccines through distribution partners, and fee-for-service contract manufacturing. The company's competitive advantage lies in its proprietary MVA-BN platform technology (Modified Vaccinia Ankara-Bavarian Nordic), which enables safer vaccine production for immunocompromised populations. Pricing power is strong for mpox vaccines given monopoly position, with government contracts typically negotiated at premium pricing ($150-200+ per dose). The business benefits from long-term government relationships and regulatory barriers to entry, though faces lumpiness from outbreak-driven demand cycles.
Mpox outbreak developments and government vaccine procurement announcements - drives 30-50% revenue swings
US and European government stockpiling contract renewals and order timing - typically multi-year agreements worth $100M-500M+
Clinical trial readouts for pipeline candidates including cancer immunotherapy programs (CV301, CV302)
Travel vaccine market share gains and geographic expansion, particularly in Asia-Pacific markets
FDA/EMA regulatory decisions on label expansions or new vaccine approvals
Mpox outbreak normalization creates structural revenue decline from 2022-2023 peak levels, with uncertainty around baseline government stockpiling demand and replenishment cycles
Single-product concentration risk with JYNNEOS representing majority of historical revenue - pipeline diversification remains years away from commercialization
Government budget constraints in US and Europe could reduce biodefense preparedness spending and delay stockpile replenishment contracts
Regulatory pathway complexity for cancer immunotherapy pipeline with high clinical trial failure rates typical in oncology
Potential competitive entry in mpox vaccine market if outbreak recurs, though regulatory barriers and manufacturing complexity provide near-term protection
Travel vaccine market competition from established players (GSK, Sanofi, Pfizer) with broader product portfolios and distribution networks
Oncology pipeline faces intense competition from checkpoint inhibitors and CAR-T therapies with more established efficacy data
Working capital volatility from lumpy government contract payments and inventory build cycles - $1.7B capex in recent period suggests significant facility investment requiring utilization
Currency exposure to USD and EUR fluctuations given international revenue base and DKK reporting currency
Burn rate risk if pipeline programs require additional capital while base vaccine business normalizes - though current cash position appears adequate
low - Vaccine demand is primarily driven by public health needs, government preparedness budgets, and regulatory mandates rather than economic cycles. Travel vaccine sales show modest correlation to discretionary travel spending during recessions, but government contracts (majority of revenue) are counter-cyclical as public health spending often increases during economic stress. The company's revenue volatility is driven by outbreak cycles rather than GDP growth.
Rising interest rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples for biotech stocks with long-duration pipeline assets, and (2) increased financing costs for working capital given lumpy government payment cycles. However, the company's minimal debt (0.01 D/E) and strong cash position ($3.84 current ratio) limit direct interest expense impact. Rate sensitivity is primarily valuation-driven rather than operational.
Minimal - The company's customers are primarily sovereign governments and large pharmaceutical partners with negligible credit risk. Strong balance sheet with minimal leverage eliminates refinancing risk. Working capital needs are manageable given government contract prepayments and milestone payments.
value - The stock attracts opportunistic value investors following the post-outbreak revenue decline, trading at 2.1x P/S and 3.8x EV/EBITDA despite strong FCF generation. The 10.9% FCF yield appeals to cash flow-focused investors. However, the stock also attracts event-driven traders around outbreak news and government contract announcements. Biotech specialists monitor pipeline progress, though the company's vaccine focus differs from typical growth biotech profiles. The -33% net income decline and -19% revenue contraction reflect normalization from outbreak peak, creating contrarian value opportunity if baseline business stabilizes.
high - Biotech stocks typically exhibit elevated volatility, and Bavarian Nordic shows pronounced swings around outbreak news, clinical trial results, and government contract timing. The 36% one-year return followed by -18% six-month decline illustrates event-driven volatility. Small-cap European biotech with limited US institutional ownership amplifies price movements. Estimated beta likely 1.3-1.5x given sector and size characteristics.
